Unit for Pharmacokinetics and Drug Metabolism, Department of Pharmacology, Institute of Neuroscience and Physiology, University of Gothenburg, Gothenburg, Sweden
Auto-generated profile, based on publicly available information
Emma Inganäs
Unit for Pharmacokinetics and Drug Metabolism, Department of Pharmacology, Institute of Neuroscience and Physiology, University of Gothenburg, Gothenburg, Sweden
Proteolysis targeting chimeras (PROTACs) offer vast new therapeutic opportunities, but their physicochemical properties are difficult to combine with optimal cell permeability and exposure at the target sites. We have systematically analyzed a data set of more than 3500 PROTACs to investigate how the choice of ubiquitin E3 ligands, linker design, and global molecular properties can be optimized to achieve the desired cell membrane interactions and ultimately membrane permeability and intracellular exposure. We find that conformational flexibility leads to environment-dependent shielding of polar functions and improved interactions with cell membranes but that at the same time, extended, linear conformations within the membrane are beneficial. Linker composition was a major factor in determining the folding propensity. Collectively, our results suggest that strategies to rationally design linkers and to shield polarity selectively within the protein-of-interest (POI) ligand and/or E3 ligand domains rather than more extensive folding may be beneficial in the design of permeable and effective PROTACs.
Proteolysis-targeting chimeras (PROTACs) occupy beyond-rule-of-5 chemical space, where cellular activity depends on molecular recognition, membrane permeation and unbound exposure at the target site. Here, we examined how these properties shape apparent E3 ligase target engagement for 20 PROTACs spanning different E3 ligase ligands, linkers, and target-binding ligands. Intracellular NanoBRET assays showed a wide range of IC50 values for competition with cereblon or VHL tracer binding when referenced to externally applied concentrations. Passive Caco-2 permeability related only weakly to these values. Recalculating IC50 values using measured intracellular unbound exposure narrowed the spread from approximately 4000-fold to 150-fold, in quantitative agreement with IC50 values measured directly in permeabilized cells. Thus, much of the apparent variation in target engagement reflects differential intracellular exposure rather than intrinsic E3 ligase recognition, and incorporating unbound exposure provides a more mechanistic basis for interpreting cellular target engagement data and distinguishing exposure-driven effects from genuine structure−activity relationships.
Antisense oligonucleotides (ASOs) are a powerful therapeutic modality, but their full potential is hindered by pharmacokinetic properties that affect tissue and cellular delivery. Lipid conjugation is increasingly used to modulate ASO’s biodistribution and promote extrahepatic activity, yet lipid-dependent effects on in vivo functional delivery, particularly in the central nervous system (CNS), remain less explored. Here, we performed a side-by-side in vivo comparison of cholesterol, palmitic acid (C16:0), docosanoic acid (C22:0), and eicosapentaenoic acid (C20:5) conjugated to a fully phosphorothioated 3-10-3 LNA gapmer ASO targeting the Malat1 long non-coding RNA. Lipid–ASO conjugates were administered systemically or locally in the brain of mice and evaluated for tissue-level and cellular-level distribution by imaging, qPCR and single-cell RNA sequencing, simultaneously annotating cell origin and global transcriptional changes within the cell. Following systemic administration in mice, lipid conjugation improved overall multi-organ efficacy compared to unconjugated ASO, but with pronounced tissue-specific differences. Single-cell sequencing of liver and heart transcriptomes revealed lipid-dependent cellular uptake patterns and transcriptional responses distinct from administration of unconjugated ASO. After intracerebroventricular administration, selected fatty acid conjugates enhanced silencing in deep brain regions such as the striatum, whereas cholesterol conjugation impaired functional delivery despite increased CNS retention. Light-sheet microscopy showed restricted parenchymal penetration of cholesterol-ASOs compared with broader but heterogeneous distribution of palmitic acid conjugate. Together, these findings demonstrate that lipid identity critically determines ASO efficacy, productive cellular uptake, and regional CNS engagement, emphasizing the need for context-specific lipid design in ASO therapeutic development. Highlights: SC, fatty acid conjugates primarily potentiate hepatic over extrahepatic silencing SC, cholesterol conjugate confines silencing activity to the liver Single-cell sequencing reveals lipid conjugate-induced differential gene expression First study reporting evaluation of lipid-ASO functional activity in the CNS via ICV delivery Chol-ASO retention at CSF-facing membranes correlates with poor parenchymal activity Graphical